FDA rejects Acacia's lead drug — again — due to the same manufacturing issue

FDA rejects Acacia's lead drug — again — due to the same manufacturing issue

Source: 
Endpoints
snippet: 

Acacia Pharma did well on the R&D front — by 2017, it had conducted four positive pivotal clinical trials for its lead drug, Barhemsys. Later that year, it submitted an FDA application to market the drug for rescue treatment of patients who develop postoperative nausea & vomiting (PONV), despite having been given prior antiemetic prophylaxis — only to receive a rejection in October 2018.